Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy

被引：0
|
作者：
Taiki Hakozaki
Yukio Hosomi
Akihiro Shimizu
Rui Kitadai
Kie Mirokuji
Yusuke Okuma
机构：
[1] Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital,Department of Thoracic Oncology and Respiratory Medicine
[2] National Cancer Center Hospital,Department of Thoracic Oncology
来源：
Journal of Cancer Research and Clinical Oncology | 2020年 / 146卷
关键词：
Polypharmacy; Non-small cell lung cancer; Overall survival; Geriatric oncology; Comorbidity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2659 / 2668
页数：9
相关论文
共 50 条
  • [31] Anti-PD-1 versus anti-PD-L1 therapy in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis
    Tartarone, Alfredo
    Roviello, Giandomenico
    Lerose, Rosa
    Roudi, Raheleh
    Aieta, Michele
    Zoppoli, Pietro
    FUTURE ONCOLOGY, 2019, 15 (20) : 2423 - 2433
  • [32] Targeting PD-L1 for non-small-cell lung cancer
    Feld, Emily
    Horn, Leora
    IMMUNOTHERAPY, 2016, 8 (06) : 747 - 758
  • [33] Complete response with anti-PD-L1 antibody following progression on anti-PD-1 antibody in advanced non-small cell lung cancer
    Singh, Navdeep
    Seetharamu, Nagashree
    BMJ CASE REPORTS, 2020, 13 (08)
  • [34] Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer
    Zhao, Sha
    Gao, Guanghui
    Li, Wei
    Li, Xuefei
    Zhao, Chao
    Jiang, Tao
    Jia, Yijun
    He, Yayi
    Li, Aiwu
    Su, Chunxia
    Ren, Shengxiang
    Chen, Xiaoxia
    Zhou, Caicun
    LUNG CANCER, 2019, 130 : 10 - 17
  • [35] Predictive Nomogram for Hyperprogressive Disease During Anti-PD-1/PD-L1 Treatment in Patients with Advanced Non-Small Cell Lung Cancer
    Wang, Xueping
    Guo, Zhixing
    Wu, Xingping
    Chen, Da
    Wang, Fang
    Yang, Lewei
    Luo, Min
    Wu, Shaocong
    Yang, Chuan
    Huang, Lamei
    Fu, Liwu
    IMMUNOTARGETS AND THERAPY, 2023, 12 : 1 - 16
  • [36] Utilizing Nanoparticles to Overcome Anti-PD-1/ PD-L1 Immunotherapy Resistance in Non-Small Cell Lung cancer: A Potential Strategy
    Ge, Yuli
    Zhou, Qiong
    Pan, Fan
    Wang, Rui
    Wang, Rui
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2025, 20 : 2371 - 2394
  • [37] Increasing membrane polyunsaturated fatty acids sensitizes non-small cell lung cancer to anti-PD-1/PD-L1 immunotherapy
    La Vecchia, Sofia
    Fontana, Simona
    Salaroglio, Iris Chiara
    Anobile, Dario Pasquale
    Digiovanni, Sabrina
    Akman, Muhlis
    Jafari, Niloufar
    Godel, Martina
    Costamagna, Costanzo
    Corbet, Cyril
    Kopecka, Joanna
    Riganti, Chiara
    CANCER LETTERS, 2024, 604
  • [38] PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
    Jing, Wang
    Li, Miaomiao
    Zhang, Yan
    Teng, Feifei
    Han, Anqin
    Kong, Li
    Zhu, Hui
    ONCOTARGETS AND THERAPY, 2016, 9 : 489 - 502
  • [39] Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in untreated advanced non-small-cell lung cancer
    Bin, Y.
    Tong, F.
    Zhang, Y.
    Zhang, R.
    Zhou, H.
    Liu, P.
    Zhang, S.
    Wang, Y.
    Yang, N.
    Dong, X.
    ANNALS OF ONCOLOGY, 2023, 34
  • [40] PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
    D'Incecco, A.
    Andreozzi, M.
    Ludovini, V.
    Rossi, E.
    Capodanno, A.
    Landi, L.
    Tibaldi, C.
    Minuti, G.
    Salvini, J.
    Coppi, E.
    Chella, A.
    Fontanini, G.
    Filice, M. E.
    Tornillo, L.
    Incensati, R. M.
    Sani, S.
    Crino, L.
    Terracciano, L.
    Cappuzzo, F.
    BRITISH JOURNAL OF CANCER, 2015, 112 (01) : 95 - 102
12345